

UC Irvine

UC Irvine Previously Published Works

Title

Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk.

Permalink

<https://escholarship.org/uc/item/5wf014h6>

Journal

Cancer Epidemiology, Biomarkers and Prevention, 24(11)

Authors

Arndt, Volker
Beckmann, Matthias
Beeghly-Fadiel, Alicia
et al.

Publication Date

2015-11-01

DOI

10.1158/1055-9965.EPI-15-0363

Peer reviewed



Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2015 November ; 24(11): 1680–1691. doi:
10.1158/1055-9965.EPI-15-0363.

Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk

A full list of authors and affiliations appears at the end of the article.

Abstract

Background—A recent association study identified a common variant (rs9790517) at 4q24 to be associated with breast cancer risk. Independent association signals and potential functional variants in this locus have not been explored.

Methods—We conducted a fine-mapping analysis in 55,540 breast cancer cases and 51,168 controls from the Breast Cancer Association Consortium.

Results—Conditional analyses identified two independent association signals among women of European ancestry, represented by rs9790517 (conditional $p = 2.51 \times 10^{-4}$; OR = 1.04; 95% CI 1.02–1.07) and rs77928427 ($p = 1.86 \times 10^{-4}$; OR = 1.04; 95% CI 1.02–1.07). Functional annotation using data from the Encyclopedia of DNA Elements (ENCODE) project revealed two putative functional variants, rs62331150 and rs73838678 in linkage disequilibrium (LD) with rs9790517 ($r^2 \geq 0.90$) residing in the active promoter or enhancer, respectively, of the nearest gene, *TET2*. Both variants are located in DNase I hypersensitivity and transcription factor binding sites. Using data from both The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), we showed that rs62331150 was associated with level of expression of *TET2* in breast normal and tumor tissue.

Conclusion—Our study identified two independent association signals at 4q24 in relation to breast cancer risk and suggested that observed association in this locus may be mediated through the regulation of *TET2*.

Impact—Fine-mapping study with large sample size warranted for identification of independent loci for breast cancer risk.

Keywords

Breast Cancer; Genetics; GWAS; 4q24; TET2

Introduction

A common genetic variant at 4q24, rs9790517, was recently identified to be associated with breast cancer risk, through a combined analysis of genome-wide association studies (GWAS) together with data from a large association study using a custom array, iCOGS (1,

*Correspondence to: Wei Zheng, MD, PhD, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, 2525 West End Avenue, 8th Floor, Nashville, TN 37203-1738, USA, Phone: (615) 936-0682; Fax: (615) 936-8241, wei.zheng@vanderbilt.edu.
The authors have no conflicts of interest to disclose.

2). This risk variant, termed subsequently as the index SNP in this paper, is located in intron 11 of *TET2*, a chromatin-remodeling gene that functions as a tumor suppressor. *TET2* has been found to be frequently somatically mutated in multiple cancers, including breast cancer (3–9). However, the index SNP is located in a region with no evidence of functional significance. The initial GWAS reported only the most strongly statistically associated SNP in this region, although many other SNPs at the same locus also may be associated with breast cancer risk, one or more of which are causally related to breast cancer risk. Comprehensive fine-scale mapping may help to identify the variants most likely to be functionally related to risk, and may enable the identification of additional independent signals.

Dense fine-scale mapping of GWAS-identified loci has successfully identified novel putative causative variants for several common diseases, including breast cancer (10–17). For example, previous fine-mapping studies of 5p15, 20q16, 2q35, 5q11 and 11q13 have identified multiple independent risk signals as well as potential causative variants in each region, using data from the Breast Cancer Association Consortium (BCAC) (12, 13, 16, 18–20). The index SNP (rs9790517) at 4q24 is close to another SNP, rs7679673 ($r^2 = 0.42$, 23 kb apart), which has been associated with prostate cancer (21). In this fine-mapping project, a dense set of SNPs in this 4q24 region was genotyped in genomic DNA samples obtained from 106,708 participants included in the BCAC. We then analyzed data from 3,912 genotyped and imputed SNPs in this region in an attempt to identify potential functional variants that may explain the observed association of genetic variants in this locus with breast cancer risk.

Materials and Methods

Study populations

The study included 55,540 breast cancer cases and 51,168 controls from 50 studies participating in the BCAC. Details of the studies, sample selection, and genotypes are described elsewhere (1). The dataset included 39 studies from European-ancestry populations (48, 155 cases and 43,612 controls), nine from Asian populations (6,269 cases and 6,624 controls) and two from populations of African ancestry (1,116 cases and 932 controls).

Genotyping of 4q24

A dense set of SNPs at 4q24 were selected for genotyping on iCOGS based on evidence of a prostate cancer associated SNP, rs7679673 (17), since at the time of the assay design this region had not yet been linked to breast cancer risk. An interval of 596kb (positions in chr4, 105932103 – 106528262 from hg19) was identified based on all SNPs with $r^2 > 0.1$ with the SNP rs7679673 based on HapMap 2 CEU (22). All SNPs in the interval were then identified from the 1000 Genomes Project CEU (April 2010)(23), together with HapMap 3, and we selected SNPs for genotyping which had an MAF $> 2\%$ in Europeans and an Illumina Design score > 0.8 . From this set, all SNPs with $r^2 > 0.1$ with SNP rs7679673 were selected, together with an additional set of SNPs to tag the remaining SNPs at $r^2 > 0.9$. In total, 490 SNPs were successfully genotyped and passed quality control. We imputed genotypes for

the remaining SNPs using the program IMPUTE2 (24) and the March 2012 release of the 1000 Genomes Project as a reference. Those imputed SNPs with common SNPs (MAF > 0.02) and imputation $r^2 > 0.3$ were included in the current analysis.

Statistical analyses

For each genotyped and imputed SNP, we evaluated its association with breast cancer risk using a logistic regression model with adjustment for age, study site and principal components to correct for potential population stratification (the first six principal components, plus one additional principal component for the LMBC in analyses of the European ancestry data, or the first two principal components in the analyses of the Asian and African ancestry data), as previously described (1). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated under a log-additive model. We conducted separate analyses within European, Asian and African American populations.

To identify independent association signals, we performed stepwise forward logistic regression analyses for the associated SNPs with an MAF > 0.02 showing association at $p < 1 \times 10^{-4}$ in the single marker SNP analysis. We used the Step function implemented in the R package (25) with the penalty $K = 10$ for inclusion of additional SNPs in the model. Since no SNPs showed $p < 1 \times 10^{-4}$ in the Asian or African populations, this analysis was performed only in the European population. The model was adjusted for the same factors as in the single SNP analysis. To define potentially causative variants, we computed a likelihood ratio for each SNP relative to the best associated SNP in each signal and excluded SNPs with a likelihood ratio < 1/100. Haplotype-specific ORs were estimated using haplo.stats in R, including age, study site, and the first six principal components, plus one additional principal component for the LMBC study.

Functional annotation

We annotated 29 candidate causative variants for potential functional significance using chromHMM annotation across nine ENCODE(26) cell lines: HMEC, GM12878, H1-hESC, K562, HepG2, HSMM, HUVEC, NHEK, and NHLF (27). For each variant, we investigated whether it is mapped to functional regions (i.e. promoter and enhancer) through chromatin states annotation from the UCSC Genome Browser (28). The epigenetic landscape of histone markers H3K4Me1, H3K4Me3, and H3K27Ac was also examined through layered histone tracks on seven ENCODE cell lines including GM12878, H1-hESC, K562, HSMM, HUVEC, NHEK, and NHLF from the UCSC Genome Browser. DNase I hypersensitive and TF ChIP-Seq datasets were investigated in all available ENCODE cell lines, including breast normal cell line, HMEC, and breast cancer cell lines, T-47D and MCF-7. Two publicly available tools, RegulomeDB (29) and HaploReg v2(30), were also used to evaluate those likely functional variants (9, 31). In addition, we also investigated whether each variant is overlapped with regulatory elements of enhancers and TSS from two previous studies including Hnisz et al (32) and Andersson et al (FANTOM5 project) (33). Chromatin Interaction Analysis by Paired End Tag (ChIA-PET) (mediated by RNA polymerase 2) data from MCF7 cell were downloaded from GEO (GSE39495) and the ggbio R package was used to represent the interactions between cell enhancers (containing a strongly associated variant) and a predicted gene promoter.

TCGA data resource and eQTL analysis

We downloaded RNA-Seq V2 data (level 3) of 1,006 breast cancer tumor tissues from the TCGA data portal (34). DNA methylation data measured by the Illumina HumanMethylation450 BeadChip were also retrieved from TCGA level 3 data. We also downloaded level 3 SNP data genotyped using the Affymetrix SNP 6.0 array. Copy Number Alteration (CNA) data for genes *PPA2*, *ARHGEF38*, *INTS12*, *GSTCD* and *TET2* at 4q24 for TCGA samples were collected from the CbioPortal (35). We analyzed a total of 645 breast tumor tissues in Caucasian population including matched CNV, genotype and expression data.

We performed eQTL analysis in TCGA tumor tissues described above. We applied several steps to reduce the batch or other technical effects on gene expressions following the approach described by Pickrell et al (36). First, the RNA-Seq by Expectation-Maximization value of each gene was log2 transformed and those genes with a median expression level of 0 across tissues were removed. We then performed the principal component correction on gene expression to remove potential batch effects. A linear regression of expression values on the first five principal components was constructed and the residuals were used to replace the expression values of each gene among tissues. To make the data better conform to the linear model for the eQTL analysis, we further transformed the gene expression levels to fit quantiles of $N(0, 1)$ distribution based on the ranks of the expression values to their respective quantiles. Residual linear regression models were constructed to detect eQTLs, while adjusting for methylation and CNA, according to the approach used by Li et al (37).

We also extracted matched genotypes and gene expression levels as described above in a total of 135 tumor-adjacent normal breast tissues in European ancestry individuals from the METABRIC project (38). Gene expression profiling was generated on the Illumina HT12 v3 microarray platform and probe-level measurements were used. Genotyping was performed on the Affymetrix SNP 6.0 with genotypes being imputed using the 1000 Genomes March 2012 CEU reference panel. Matrix eQTL was performed for evaluating the association between genotypes and gene expression levels (39).

Results

Association Analyses

We evaluated associations for 490 genotyped and 3,422 well-imputed SNPs at 4q24 spanning 596 kb (positions in chr4: 105932103 – 106528262 from hg19) in 48,155 cases and 43,612 controls of European descent. A total of 29 variants were significantly associated with breast-cancer risk at $p < 1 \times 10^{-4}$ (Figure 1, Supplementary Table 1). Of these, 15 variants were directly genotyped and 14 were imputed with $r^2 > 0.9$. All risk-associated variants had minor allele frequencies (MAF) > 0.05 . The index SNP, rs9790517, showed strong evidence of a significant association with breast cancer risk (OR = 1.05; 95% CI 1.03–1.08; $p = 5.44 \times 10^{-6}$), which was consistent with the report from the original study (1). The strongest association was, however, found for an imputed SNP rs73838678 (OR = 1.12, 95% CI 1.07–1.17; $p = 1.29 \times 10^{-6}$).

To identify potential independent association signals, we carried out forward stepwise logistic regression analysis on SNPs associated with breast cancer at $p < 1 \times 10^{-4}$. Two independent association signals were revealed: index SNP rs9790517 (conditional $p = 2.51 \times 10^{-4}$, after adjustment for the SNP in the second signal) and SNP rs77928427 (conditional $p = 1.86 \times 10^{-4}$ after adjusting for the index SNP) (Table 1). The index SNP rs9790517 in signal 1 was in weak LD with the SNP rs77928427 in the second risk signal ($r^2 = 0.04$). These two SNPs are more than 300kb from each other.

We performed similar analyses, restricting to cases with estrogen receptor positive (ER+) cancer and identified 17 variants associated with ER+ breast cancer risk at $p < 1 \times 10^{-4}$ in women of European ancestry. No SNP was found to be associated with ER-negative (ER-) disease at $p < 1 \times 10^{-4}$. However, the per-allele ORs for the two SNPs independently associated with overall breast cancer risk were similar for ER- and ER+ disease (Table 1; all tests of heterogeneity by ER-status $p > 0.10$). Conditional analysis yielded similar associations for ER+ breast cancer to those for overall breast cancer for the two independently associated SNPs.

We performed haplotype analysis based on the top SNPs from the two signals: rs9790517 and rs77928427 in European descendants. Three major haplotypes were observed. Compared with the most common haplotype carrying the common allele at both SNPs, haplotype TA carrying two risk alleles showed the strongest association with breast cancer risk (OR = 1.11; 95% CI 1.07–1.15; $p = 2.31 \times 10^{-8}$) (Table 2). The frequency of this haplotype was 9.4%. Haplotypes CA and TC, carrying the risk allele in either signal 1 or 2, also were associated with elevated risk of breast cancer, although the association was only marginally significant. Thus, the haplotype analyses were consistent with the hypothesis that there are two independently associated variants in the region.

We compared the average age among those cases carrying risk and non-risk alleles of rs9790517. Interestingly, we observed that the cases carrying risk alleles were slightly younger than those carrying non-risk alleles (average age: 57.54, 57.62 and 57.64 respectively for patients carrying alleles TT, TC and CC of rs9790517; $p < 2 \times 10^{-16}$). No such pattern was observed for rs77928427.

We carried out association analysis for all SNPs with breast cancer in subjects of Asian and African descent. None of the SNPs identified in women of European ancestry as associated at $p < 10^{-4}$ showed a significant association in either Asians or African women at $p < 0.05$ (Table 3). However, the 95%CI for the OR estimates in Asians and Africans included the point estimate in Europeans for both of the two top independent SNPs. We found one SNP associated with breast cancer risk in Asians and three in Africans, at $p < 0.01$ (strongest signal rs1116764: OR 1.10; 95% CI 1.04–1.16; $p = 4.21 \times 10^{-4}$), none of these SNPs were in LD with the two independent association signals identified in European women (Table 3).

Functional Annotation

We used a likelihood ratio $> 1:100$ relative to the best associated SNP in each signal to select candidate variants for functional annotation in order to identify potentially causative variants in this region (Supplementary Table 1). In total, 29 SNPs were identified including

24 for signal 1 and 5 for signal 2. Of these, 17 SNPs in signal 1 were strongly correlated with the original index SNP rs9790517, and the remainder were more weakly correlated. All SNPs were evaluated using DNase-Seq and ChIP-Seq data from the ENCODE project. The most promising evidence for functionality was found for SNPs rs62331150 and rs73838678, both in LD with rs9790517 ($r^2 = 0.98$ and $r^2 = 0.09$, respectively) in signal 1. The annotation from chromatin states (27) revealed that rs62331150 resides in an active promoter region, and rs73838678 in a strong enhancer region, on several ENCODE cell lines including HMEC (Human Mammary Epithelial Cell) but not for other SNPs in either signal 1 or 2 (Figure 2A). The active promoter associated histone marks (H3K4Me3 and H3K27Ac) and enhancer associated histone marker H3K27Ac were enriched in the intervals containing rs62331150 and rs73838678, respectively, in several ENCODE cells, and both SNPs were also found to be located in or near a DNase I hypersensitive site (DHS) (Figure 2A, B). In addition, both variants were found to overlap with predicted enhancer regions of *TET2* in multiple cells including HMEC as reported in a recent study (32). None of the other SNPs in signal 1, and none of the 5 SNPs in signal 2 fell into a strong annotated promoter or enhancer region in those cells.

To identify putative gene targets, we examined the annotation of TSS and TSS-associated enhancers using Cap Analysis of Gene Expression (CAGE) from the FANTOM5 project (23). We found that rs62331150 and rs73838678 reside in regulatory elements of enhancers associated with transcription start sites (TSS) and TSS of *TET2* in multiple cells (Figure 2A). We also examined potential functional chromatin interactions between distal and proximal regulatory transcription-factor binding sites and the promoters at the risk regions using ChIA-PET data. ChIA-PET data for Pol2 in MCF-7 breast tumor derived cells showed multiple chromosomal interactions across the entire region, but these interactions were particularly dense in the vicinity of the *TET2* promoter region, encompassing the strongest candidate causal variant rs62331150 and rs73838678 (Figure 2A).

A search of RegulomeDB indicated that rs62331150 and rs73838678 were annotated to lie in the breast cancer related transcription factor (TF) SP1 (Specificity Protein 1) and PR (progesterone receptor) (40, 41) predicted binding motifs, respectively (Figure 2B). We observed that the G nucleotide was more frequently found in the SP1 motif than the T nucleotide, indicating that the SP1 may preferentially bind to the reference G allele (Figure 2B). For variant rs73838678, no significant allelic frequency difference in the PR motif was observed. Using ChIP-Seq data from a total of 161 TFs from the ENCODE project (ChIP-Seq V3), we found that both variants are located in multiple TF binding sites (Figure 2B). As an example, ChIP-Seq binding peaks of breast cancer-related TFs, EGR1 and NIFC, harbor the variant rs62331150 and rs73838678, respectively (42, 43). In particular, we observed that P300, marking the active enhancer, was found to bind close to both variants in multiple ENCODE cell lines, suggesting that the variant in the region may lead to *TET2* transcriptional activation.

Gene expression analyses

We used both The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) data to examine the association of the

putative functional SNP rs62331150 and rs73838678 with expression of *TET2* and several other neighboring genes, including *PPA2*, *ARHGEF38*, *INTS12*, and *GSTCD*, in breast cancer tissues. No significant correlations with any genes were observed for variant rs73838678. Variant rs62331150 was weakly correlated with *TET2* expression in both datasets ($p = 0.039$ and $p = 0.025$ respectively for TCGA and METABRIC), the reference allele *G* being associated with increased expression relative to the risk allele *T* (Figure 3). The result was consistent with the observation from our functional annotation that SP1 may preferentially bind to the reference *G* allele, leading to a significant increase in *TET2* transcription activation. No correlation between rs62331150 and the expression of any other gene in the region was found in either dataset. Overall, our findings supported a hypothesis that *TET2* is the target gene for the signal 1 association, and that the association with breast cancer risk may be mediated through regulation of *TET2* gene expression. The result is also in line with previous findings that *TET2* functions as a tumor suppressor and its high expression level may reduce breast cancer risk (44, 45).

Discussion

In this study, we identified two independent association signals at 4q24 in women of European ancestry. Statistical analyses reduced the set of likely causative variants to 29. Using functional genomic data, we provided strong evidence for two variants as functional variants. Our study suggests that the breast cancer risk may be mediated through their regulation of *TET2* gene expression.

In our initial single marker analysis, we observed that the majority of variants, including the index SNP, were located in or near the *TET2* gene region. Through eQTL analysis based on TCGA data, we found that multiple SNPs in signal 1 were correlated with *TET2* expression, which was expected given their strong LD with each others. Of those SNPs, rs62331150 resides in the promoter of *TET2*. Although eQTL analysis is helpful to identify potential target genes, it is difficult to use eQTL results to pinpoint the causal variant particularly when multiple SNPs are in strong LD. In addition to residing in the promoter region of the *TET2*, the variant rs62331150 was also found to be located in the binding sites of multiple TFs including the breast cancer related TF EGR1, potentially affecting the binding affinities of specific TFs. Interestingly, the putative functional SNP rs62331150 is close to SNP rs7679673 that has been associated with prostate cancer risk (21), indicating that *TET2* gene may also be involved in prostate cancer risk. In comparison to rs62331150, rs73838678 in signal 1 was not found to have a significant association with *TET2* and any other nearby genes. One possible reason is that the statistical power is low for rs73838678 due to its relative low allele frequency (MAF = 0.049). We also could not exclude the other possible target genes for rs73838678. Future studies using *in vitro* and *in vivo* assays are warranted to verify this conclusion.

Cumulative evidence shows that *TET2* has an important function in tumor suppression. This gene can alter the epigenetic status of DNA base methylcytosine to 5-hydroxymethylcytosine and therefore, have a genome-wide scale of influence on gene expression (46–48). Accordingly, *TET2* gene dysregulation could cause aberrant DNA methylations and consequently contribute to cancer development (3–6, 45, 49). Here, we

reported *TET2* as a candidate susceptibility gene for both ER+ and ER– breast cancer types. Although the associations for the top SNPs, rs9790517 and rs77928427, with breast cancer risk in Asian and African-ancestry populations were not statistically significant, likely due to a small sample size, the direction of the associations was mostly consistent in all population, suggesting that the *TET2* gene play a similar role in the etiology of breast cancer in all three populations.

Although our fine-mapping analysis represents the most comprehensive analysis of variants at 4q24 thus far, many SNPs, particularly rare variants, cannot be imputed. Deep sequencing of this region may reveal additional risk variants for breast cancer. For example, rs76682196, located 884 bp upstream of rs62331150, was found to be potentially functional using the ENCODE data. The variant is present in DHS and TFs sites. In particular, it lies in the ER α (Estrogen Receptor- α) predicted binding motif and ChIP-Seq peak in breast cancer cell line T-47D. However, this variant was not included in the study due to its low frequency (MAF < 0.01) in populations from all three ethnic groups.

In conclusion, this dense fine-mapping study identified two independent association signals with breast cancer risk at 4q24, increasing the estimated familial relative risk of breast cancer explained by this locus from the original 0.07% to 0.15% among women of European descent. Functional analyses revealed one potentially functional variant, rs62331150. The risk allele is associated with lower expression of *TET2*, consistent with previous findings that this gene acts as a tumor suppressor.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Xingyi Guo¹, Jirong Long¹, Chenjie Zeng¹, Kyriaki Michailidou², Maya Ghoussaini³, Manjeet K. Bolla², Qin Wang², Roger L. Milne^{4,5}, Xiao-Ou Shu¹, Qiuyin Cai¹, Jonathan Beesley⁶, Siddhartha P. Kar³, Irene L. Andrulis^{7,8}, Hoda Anton-Culver⁹, Volker Arndt¹⁰, Matthias W. Beckmann¹¹, Alicia Beeghly-Fadiel¹, Javier Benitez^{12,13}, William Blot^{1,14}, Natalia Bogdanova¹⁵, Stig E. Bojesen^{16,17,18}, Hiltrud Brauch^{19,20,21}, Hermann Brenner^{10,21,22}, Louise Brinton²³, Annegien Broeks²⁴, Thomas Brüning²⁵, Barbara Burwinkel^{26,27}, Hui Cai¹, Sander Canisius²⁸, Jenny Chang-Claude²⁹, Ji-Yeob Choi^{30,31}, Fergus J. Couch³², Angela Cox³³, Simon S. Cross³⁴, Kamila Czene³⁵, Hatem Darabi³⁵, Peter Devilee^{36,37}, Arnaud Droit³⁸, Thilo Dörk³⁹, Peter A. Fasching^{11,40}, Olivia Fletcher⁴¹, Henrik Flyger⁴², Florentia Fostira⁴³, Valerie Gaborieau⁴⁴, Montserrat García-Closas^{45,41}, Graham G. Giles^{4,5}, Mervi Grip⁴⁶, Pascal Guénel^{47,48}, Christopher A. Haiman⁴⁹, Ute Hamann⁵⁰, Mikael Hartman^{51,52}, Antoinette Hollestelle⁵³, John L. Hopper⁵, Chia-Ni Hsiung⁵⁴, kConFab Investigators⁵⁵, Hidemi Ito⁵⁶, Anna Jakubowska⁵⁷, Nichola Johnson⁴¹, Maria Kabisch⁵⁰, Daehee Kang^{58,30,31}, Sofia Khan⁵⁹, Julia A. Knight^{60,61}, Veli-Matti Kosma⁶², Diether Lambrechts^{63,64}, Loïc Le Marchand⁶⁵, Jingmei Li³⁵, Annika Lindblom⁶⁶, Artitaya Lophatananon⁶⁷, Jan Lubinski⁵⁷, Arto Mannermaa⁶²,

Siranoush Manoukian⁶⁸, Sara Margolin⁶⁹, Frederik Marme^{70,71}, Keitaro Matsuo⁷², Catriona A. McLean⁷³, Alfons Meindl⁷⁴, Kenneth Muir^{68,75}, Susan L. Neuhausen⁷⁶, Heli Nevanlinna⁵⁹, Silje Nord^{77,78}, Janet E. Olson⁷⁹, Nick Orr⁸⁰, Paolo Peterlongo⁸¹, Thomas Choudary Putti⁸², Anja Rudolph²⁹, Suleeporn Sangrajang⁸³, Elinor J. Sawyer⁸⁴, Marjanka K. Schmidt²⁴, Rita K. Schmutzler^{85,86,87,88}, Chen-Yang Shen^{89,90}, Jiajun Shi¹, Martha J Shrubsole¹, Melissa C. Southey⁹¹, Anthony Swerdlow⁹², Soo Hwang Teo^{93,94}, Bernard Thienpont^{63,64}, Amanda Ewart Toland⁹⁵, Robert A.E.M. Tollenaar⁹⁶, Ian P.M. Tomlinson⁹⁷, Thérèse Truong^{47,48}, Chiu-chen Tseng⁴⁹, Ans van den Ouweland⁹⁸, Wanqing Wen¹, Robert Winqvist^{99,100}, Anna Wu⁴⁹, Cheng Har Yip⁹⁴, M. Pilar Zamora¹⁰¹, Ying Zheng¹⁰², Per Hall³⁵, Paul D.P. Pharoah^{2,3}, Jacques Simard³⁸, Georgia Chenevix-Trench⁶, Alison M. Dunning³, Douglas F. Easton^{2,3}, and Wei Zheng^{1,*}

Affiliations

¹Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA ²Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK ³Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK ⁴Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia ⁵Centre for Epidemiology and Biostatistics, School of Population and Global health, The University of Melbourne, Melbourne, Victoria, Australia ⁶Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia ⁷Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada ⁸Department of Molecular Genetics, University of Toronto, Toronto, Canada ⁹Department of Epidemiology, University of California Irvine, Irvine, CA, USA ¹⁰Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany ¹¹Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany ¹²Human Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid, Spain ¹³Centro de Investigación en Red de Enfermedades Raras, Valencia, Spain ¹⁴International Epidemiology Institute, Rockville, MD, USA ¹⁵Department of Radiation Oncology, Hannover Medical School, Hannover, Germany ¹⁶Copenhagen General Population Study, Herlev Hospital, Herlev, Denmark ¹⁷Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark ¹⁸Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark ¹⁹Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany ²⁰University of Tübingen, Tübingen, Germany ²¹German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany ²²Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany ²³Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA ²⁴Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands ²⁵Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Bochum, Germany ²⁶Division of Molecular Genetic

Epidemiology, German Cancer Research Center, Heidelberg, Germany ²⁷Molecular Epidemiology Group, German Cancer Research Center, Heidelberg, Germany ²⁸Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands ²⁹Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany ³⁰Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea ³¹Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea ³²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA ³³Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, UK ³⁴Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK ³⁵Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden ³⁶Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands ³⁷Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands ³⁸Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec, Canada ³⁹Gynaecology Research Unit, Hannover Medical School, Hannover, Germany ⁴⁰David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA ⁴¹Division of Cancer Studies, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK ⁴²Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark ⁴³Molecular Diagnostics Laboratory, IRRP, National Centre for Scientific Research "Demokritos", Athens, Greece ⁴⁴International Agency for Research on Cancer, Lyon, France ⁴⁵Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK ⁴⁶Department of Surgery, Oulu University Hospital and University of Oulu, Oulu, Finland ⁴⁷Environmental Epidemiology of Cancer, Center for Research in Epidemiology and Population Health, INSERM, Villejuif, France ⁴⁸University Paris-Sud, Villejuif, France ⁴⁹Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA ⁵⁰Molecular Genetics of Breast Cancer, German Cancer Research Center, Heidelberg, Germany ⁵¹Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore ⁵²Department of Surgery, National University Health System, Singapore ⁵³Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands ⁵⁴Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan ⁵⁵Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia ⁵⁶Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Aichi, Japan ⁵⁷Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland ⁵⁸Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea ⁵⁹Department of Obstetrics and Gynecology, Helsinki University Central Hospital, University of Helsinki, Helsinki, FI-00029 HUS, Finland ⁶⁰Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, M5G 1X5, Canada ⁶¹Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, M5S 1A8, Canada

⁶²School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine and Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland; Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland ⁶³Vesalius Research Center, Leuven, Belgium ⁶⁴Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Leuven, Belgium ⁶⁵University of Hawaii Cancer Center, Honolulu, HI, USA ⁶⁶Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm SE, Sweden ⁶⁷Division of Health Sciences, Warwick Medical School, Warwick University, Coventry, UK ⁶⁸Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy ⁶⁹Department of Oncology - Pathology, Karolinska Institutet, Stockholm SE, Sweden ⁷⁰National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany ⁷¹Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany ⁷²Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan ⁷³Anatomical Pathology, The Alfred Hospital, Melbourne, Victoria, Australia ⁷⁴Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany ⁷⁵Institute of Population Health, University of Manchester, Manchester, UK ⁷⁶Beckman Research Institute of City of Hope, Duarte, CA, USA ⁷⁷Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Ullernchausseen, Oslo, Norway ⁷⁸K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Kirkeveien, Oslo, Norway ⁷⁹Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA ⁸⁰Division of Breast Cancer Research, Institute of Cancer Research, London, UK; Cancer Research, Institute of Cancer Research, London, UK ⁸¹IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy ⁸²Department of Pathology, National University Health System, Singapore ⁸³National Cancer Institute, Bangkok, Thailand ⁸⁴Research Oncology, Guy's Hospital, King's College London, London, UK ⁸⁵Division of Molecular Gyneco-Oncology, Department of Gynaecology and Obstetrics, University Hospital of Cologne, Cologne, Germany ⁸⁶Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany ⁸⁷Center for Molecular Medicine, University Hospital of Cologne, Cologne, Germany ⁸⁸Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany ⁸⁹School of Public Health, China Medical University, Taichung, Taiwan ⁹⁰Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan ⁹¹Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia ⁹²Division of Genetics and Epidemiology and Division of Breast Cancer Research, Institute of Cancer Research, London, UK ⁹³Cancer Research Initiatives Foundation, Subang Jaya, Selangor, Malaysia ⁹⁴Breast Cancer Research Unit, Cancer Research Institute, University Malaya Medical Centre, Kuala Lumpur, Malaysia ⁹⁵Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA ⁹⁶Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands ⁹⁷Wellcome Trust Centre for Human Genetics and Oxford Biomedical

Research Centre, University of Oxford, Oxford, UK ⁹⁸Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands ⁹⁹Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry, University of Oulu, Oulu, Finland ¹⁰⁰Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre NordLab, Oulu, Finland ¹⁰¹Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain ¹⁰²Shanghai Municipal Center for Disease Control and Prevention, Shanghai, PR China

Acknowledgment

We thank all the individuals who took part in these studies and all the researchers, study staff, clinicians and other healthcare providers, technicians and administrative staff who have enabled this work to be carried out. In particular, we thank: Andrew Berchuck (OCAC), Rosalind A. Eeles, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Antonis Antoniou, Lesley McGuffog, Ken Offit (CIMBA), Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière, Frederic Robidoux and the staff of the McGill University and Génomique Québec Innovation Centre, Sune F. Nielsen and the staff of the Copenhagen DNA laboratory, Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility, Maggie Angelakos, Judi Maskiell, Ellen van der Schoot (Sanquin Research), Emiel Rutgers, Senno Verhoef, Frans Hogervorst, the Thai Ministry of Public Health (MOPH), Dr Prat Boonyawongviroj (former Permanent Secretary of MOPH), Dr Pornthep Siriwanarungsan (Department Director-General of Disease Control), Michael Schrauder, Matthias Rübner, Sonja Oeser, Silke Landrith, Eileen Williams, Elaine Ryder-Mills, Kara Sargus, Niall McInerney, Gabrielle Collieran, Andrew Rowan, Angela Jones, Christof Sohn, Andreas Schneeweiß, Peter Bugert, the Danish Breast Cancer Group, Núria Álvarez, the CTS Steering Committee (including Leslie Bernstein, James Lacey, Sophia Wang, Huiyan Ma, Yani Lu and Jessica Clague DeHart at the Beckman Research Institute of the City of Hope; Dennis Deapen, Rich Pinder, Eunjung Lee and Fred Schumacher at the University of Southern California; Pam Horn-Ross, Peggy Reynolds and David Nelson at the Cancer Prevention Institute of California; and Hannah Park at the University of California Irvine), Hartwig Ziegler, Sonja Wolf, Volker Hermann, The GENICA network [Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Germany; (HB, Wing-Yee Lo, Christina Justenhoven), German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) [HB] Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanner Krankenhaus, Bonn, Germany (Yon-Dschun Ko, Christian Baisch), Institute of Pathology, University of Bonn, Germany (Hans-Peter Fischer), Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Germany (Ute Hamann), Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Germany (TB, Beate Pesch, Sylvia Rabstein, Anne Lotz), Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Germany (Volker Harth)], Tuomas Heikkinen, Irja Erkkilä, Kirsimari Aaltonen, Karl von Smitten, Natalia Antonenkova, Peter Hillemanns, Hans Christiansen, Eija Myöhänen, Helena Kemiläinen, Heather Thorne, Eveline Niedermayr, the AOCs Management Group (D Bowtell, G Chenevix-Trench, A deFazio, D Gertig, A Green, P Webb), the ACS Management Group (A. Green, P. Parsons, N. Hayward, P. Webb, D. Whiteman), the LAABC data collection team, especially Annie Fung and June Yashiki, Gilian Peuteman, Dominiek Smeets, Thomas Van Brussel, Kathleen Corthouts, Nadia Obi, Judith Heinz, Sabine Behrens, Ursula Eilber, Muhabbet Celik, Til Olchers, Siranoush Manoukian, Bernard Peissel, Giulietta Scuvera, Daniela Zaffaroni, Bernardo Bonanni, Irene Feroce, Angela Maniscalco, Alessandra Rossi, Loris Bernard, the personnel of the Cogentech Cancer Genetic Test Laboratory, The Mayo Clinic Breast Cancer Patient Registry, Martine Tranchant, Marie-France Valois, Annie Turgeon, Lea Heguy, Phuah Sze Yee, Peter Kang, Kang In Nee, Shivaani Mariapun, Yoon Sook-Yee, Daphne Lee, Teh Yew Ching, Nur Aishah Mohd Taib, Meeri Otsukka, Kari Mononen, Teresa Selander, Nayana Weerasooriya, OFBCR staff, E. Krol-Warmerdam, J. Molenaar, J. Blom, Louise Brinton, Neonila Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao, Michael Stagner, Petra Bos, Jannet Blom, Ellen Crepin, Anja Nieuwlaet, Annette Heemskerk, the Erasmus MC Family Cancer Clinic, Sue Higham, Simon Cross, Helen Cramp, Dan Connley, Sabapathy Balasubramanian, Ian Brock, The Eastern Cancer Registration and Information Centre, the SEARCH and EPIC teams, Michael Kerin, Nicola Miller, Niall McInerney, Gabrielle Collieran (BIGGS), Pierre Kerbrat, Patrick Arveux; Romuald Le Scodan; Yves Raoul; Pierre Laurent-Puig; Claire Mulot (CECILE), Christa Stegmaier and Katja Butterbach (ESTHER), Natalia Antonenkova, Peter Hillemanns, Hans Christiansen and Johann H. Karstens (HMBCS), Gilian Peuteman, Dominiek Smeets, Thomas Van Brussel and Kathleen Corthouts (LMBC), Dieter Flesch-Janys, Petra Seibold, Judith Heinz, Nadia Obi, Alina Vrieling, Sabine Behrens, Ursula Eilber, Muhabbet Celik, Til Olchers and Stefan Nickels (MARIE). We wish to thank Paolo Radice, Bernard Peissel and Daniela Zaffaroni of the Fondazione IRCCS Istituto Nazionale dei Tumori (INT); Bernardo Bonanni, Monica Barile and Irene Feroce of the Istituto Europeo di Oncologia (IEO) and Loris Bernard

and the personnel of the Cogentech Cancer Genetic Test Laboratory. Cancer Council Victoria acknowledges the Traditional Owners of the land and waters throughout Victoria and pays respect to them, their culture and their Elders past, present and future. We would like to thank Martine Tranchant (Cancer Genomics Laboratory, CHU de Québec Research Center), Marie-France Valois, Annie Turgeon and Lea Heguy (McGill University Health Center, Royal Victoria Hospital; McGill University) for DNA extraction, sample management and skillful technical assistance. J.S. is Chairholder of the Canada Research Chair in Oncogenetics. OBCS thanks Katri Pylkäs, Arja Jukkola-Vuorinen, Salla Kauppila, Kari Mononen and Meeri Otsukka for data collection and sample preparation. OBCS thanks Katri Pylkäs, Arja Jukkola-Vuorinen, Salla Kauppila, Kari Mononen and Meeri Otsukka for data collection and sample preparation. Craig Luccarini, Don Conroy, Caroline Baynes, Kimberley Chua, the Ohio State University Human Genetics Sample Bank and Robert Pilarski. Data on SCCS cancer cases used in this publication were provided by the: Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia Department of Health, Virginia Cancer Registry; Arkansas Department of Health, Cancer Registry.

Grant Support

The work conducted for this project at Vanderbilt Epidemiology Center is supported in part by NIH grant R37CA070867 and endowment funds for the Ingram Professorship and Anne Potter Wilson Chair. BCAC is funded by Cancer Research UK (C1287/A10118, C1287/A12014) and by the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS). Meetings of the BCAC have been funded by the European Union COST programme (BM0606). Genotyping of the iCOGS array was funded by the European Union (HEALTH-F2-2009-223175), Cancer Research UK (C8197/A16565 and C1287/A10710), the Canadian Institutes of Health Research for the 'CIHR Team in Familial Risks of Breast Cancer' program and the Ministry of Economic Development, Innovation and Export Trade of Quebec (PSR-SIIRI-701). Additional support for the iCOGS infrastructure was provided by the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112—the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. This work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow and M.C.S. is a NHMRC Senior Research Fellow. The OFBCR work was also supported by the Canadian Institutes of Health Research 'CIHR Team in Familial Risks of Breast Cancer' program. The ABCS was funded by the Dutch Cancer Society Grant no. NKI2007-3839 and NKI2009-4363. The ACP study is funded by the Breast Cancer Research Trust, UK. The work of the BBCC was partly funded by ELAN-Programme of the University Hospital of Erlangen. The BBCC is funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). E.S. is supported by NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, UK. Core funding to the Wellcome Trust Centre for Human Genetics was provided by the Wellcome Trust (090532/Z/09/Z). I.T. is supported by the Oxford Biomedical Research Centre. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center (DKFZ). The CECILE study was funded by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Sécurité Sanitaire (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council and Herlev Hospital. The CNIO-BCS was supported by the Genome Spain Foundation, the Red Temática de Investigación Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI11/00923 and PI081120). The Human Genotyping-CEGEN Unit, CNIO is supported by the Instituto de Salud Carlos III. D.A. was supported by a Fellowship from the Michael Manzella Foundation (MMF) and was a participant in the CNIO Summer Training Program. The CTS was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398). Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. HAC receives support from the Lon V Smith Foundation (LVS39420). The ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus Bonn, Germany.

The HEBCS was supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, The Nordic Cancer Union and the Sigrid Juselius Foundation. The HERPACC was supported by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from Ministry Health, Labour and Welfare of Japan, by a research grant from Takeda Science Foundation, by Health and Labour Sciences Research Grants for Research on Applying Health Technology from Ministry Health, Labour and Welfare of Japan and by National Cancer Center Research and Development Fund. The HMBCS was supported by the Rudolf Bartling Foundation. Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Stockholm Cancer Foundation and the Swedish Cancer Society. The KBCP was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, the Academy of Finland and by the strategic funding of the University of Eastern Finland. kConFab is supported by grants from the National Breast Cancer Foundation, the NHMRC, the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia and the Cancer Foundation of Western Australia. The kConFab Clinical Follow Up Study was funded by the NHMRC (145684, 288704, 454508). Financial support for the AOCs was provided by the United States Army Medical Research and Materiel Command (DAMD17-01-1-0729), the Cancer Council of Tasmania and Cancer Foundation of Western Australia and the NHMRC (199600). G.C.T. and P.W. are supported by the NHMRC. LAABC is supported by grants (1RB-0287, 3PB-0102, 5PB-0018 and 10PB-0098) from the California Breast Cancer Research Program. Incident breast cancer cases were collected by the USC Cancer Surveillance Program (CSP) which is supported under subcontract by the California Department of Health. The CSP is also part of the National Cancer Institute's Division of Cancer Prevention and Control Surveillance, Epidemiology, and End Results Program, under contract number N01CN25403. LMBC is supported by the 'Stichting tegen Kanker' (232-2008 and 196-2010). Diether Lambrechts is supported by the FWO and the KULPFV/10/016-SymBioSysII and by a ERC consolidator grant. The MARIE study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419], the Hamburg Cancer Society, the German Cancer Research Center and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated a 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects '5 × 1000'). The MCBSCS was supported by the NIH grants (CA122340, CA128978) and a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. The MEC was supported by NIH grants CA63464, CA54281, CA098758 and CA132839. The work of MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program – grant # CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade – grant # PSR-SIIRI-701. MYBRCA is funded by research grants from the Malaysian Ministry of Science, Technology and Innovation (MOSTI), Malaysian Ministry of Higher Education (UM.C/HIR/MOHE/06) and Cancer Research Initiatives Foundation (CARIF). Additional controls were recruited by the Singapore Eye Research Institute, which was supported by a grant from the Biomedical Research Council (BMRC08/1/35/19<tel:08/1/35/19>/550), Singapore and the National medical Research Council, Singapore (NMRC/CG/SERI/2010). The NBCS was supported by grants from the Norwegian Research council (155218/V40, 175240/S10 to A.L.B.D., FUGE-NFR 181600/V11 to V.N.K. and a Swizz Bridge Award to A.L.B.D.). Silje Nord has a carrier grant from the Health Region South East (HSØ, grant nr 2014061). The NBHS was supported by NIH grant R01CA100374.

Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. OBCS was supported by the Academy of Finland (grant number 250083, 122715 and Center of Excellence grant number 251314), the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the University of Oulu, the University of Oulu Support Foundation and the special Governmental EVO funds for Oulu University Hospital -based research activities. The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. pKARMA is a combination of the KARMA and LIBRO-1 studies. KARMA was supported by Märit and Hans Rausing's Initiative Against Breast Cancer. KARMA and LIBRO-1 were supported the Cancer Risk Prediction Center (CRiSP; www.crispcenter.org), a Linnaeus Centre (Contract ID 70867902) financed by the Swedish Research Council. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). SASBAC was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. KC was financed by the Swedish Cancer Society (5128-B07-01PAF). The SBCGS was supported primarily by NIH grants R01CA64277, R01CA148667, and R37CA70867. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The SBCS was supported by Yorkshire Cancer Research S305PA, S299 and S295, and the Sheffield Experimental Cancer Medicine Centre. Funding for the SCCS was provided by NIH grant R01 CA092447. The Arkansas Central Cancer

Registry is fully funded by a grant from National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC). Data on SCCS cancer cases from Mississippi were collected by the Mississippi Cancer Registry which participates in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Mississippi Cancer Registry. SEARCH is funded by a programme grant from Cancer Research UK (C490/A10124) and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The SEBCS was supported by the BRL (Basic Research Laboratory) program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012-0000347). SGBCC is funded by the NUS start-up Grant, NCIS Centre Grant and NMRC Clinician Scientist Award. Additional controls were recruited by the Singapore Consortium of Cohort Studies-Multi-ethnic cohort (SCCS-MEC), which was funded by the Biomedical Research Council, grant number: 05/1/21/19/425. SKKDKFZS is supported by the DKFZ. The SZBCS was supported by Grant PBZ_KBN_122/P05/2004. K. J. is a fellow of International PhD program, Postgraduate School of Molecular Medicine, Warsaw Medical University, supported by the Polish Foundation of Science. The TNBCC was supported by the NIH grant (CA128978), the Breast Cancer Research Foundation, Komen Foundation for the Cure, the Ohio State University Comprehensive Cancer Center, the Stefanie Spielman Fund for Breast Cancer Research and a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation. Part of the TNBCC (DEMOKRITOS) has been co-financed by the European Union (European Social Fund – ESF) and Greek National Funds through the Operational Program ‘Education and Lifelong Learning’ of the National Strategic Reference Framework (NSRF)—Research Funding Program of the General Secretariat for Research & Technology: ARISTEIA. The TWBCS is supported by the Institute of Biomedical Sciences, Academia Sinica and the National Science Council, Taiwan. The UKBGS is funded by Breakthrough Breast Cancer and the Institute of Cancer Research (ICR). ICR acknowledges NHS funding to the NIHR Biomedical Research Centre.

References

1. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nature genetics*. 2013; 45:353–361. 61e1-2. [PubMed: 23535729]
2. iCOGs [Internet]. Cambridge (UK): Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care/Department of Oncology, University of Cambridge; Available from: <http://ccge.medschl.cam.ac.uk/research/consortia/icogs/>
3. Tefferi A, Lim KH, Levine R. Mutation in TET2 in myeloid cancers. *The New England journal of medicine*. 2009; 361:1117. author reply -8. [PubMed: 19741235]
4. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. *The New England journal of medicine*. 2009; 360:2289–2301. [PubMed: 19474426]
5. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *The New England journal of medicine*. 2013; 368:2059–2074. [PubMed: 23634996]
6. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer cell*. 2010; 18:553–567. [PubMed: 21130701]
7. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. *Nature*. 2012; 488:660–664. [PubMed: 22895193]
8. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. *Nature*. 2012; 486:400–404. [PubMed: 22722201]
9. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome research*. 2012; 22:1790–1797. [PubMed: 22955989]
10. Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. *Nature genetics*. 2012; 44:1137–1141. [PubMed: 22961000]
11. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. *Nature genetics*. 2011; 43:1193–1201. [PubMed: 22057235]

12. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature genetics*. 2013; 45:371–384. 84e1-2. [PubMed: 23535731]
13. Meyer KB, O'Reilly M, Michailidou K, Carlebur S, Edwards SL, French JD, et al. Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *American journal of human genetics*. 2013; 93:1046–1060. [PubMed: 24290378]
14. Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Dadaev T, Jugurnauth-Little S, et al. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. *Human molecular genetics*. 2013; 22:2520–2528. [PubMed: 23535824]
15. Gong J, Schumacher F, Lim U, Hindorff LA, Haessler J, Buyske S, et al. Fine Mapping and Identification of BMI Loci in African Americans. *American journal of human genetics*. 2013; 93:661–671. [PubMed: 24094743]
16. French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *American journal of human genetics*. 2013; 92:489–503. [PubMed: 23540573]
17. Hughes T, Coit P, Adler A, Yilmaz V, Aksu K, Duzgun N, et al. Identification of multiple independent susceptibility loci in the HLA region in Behcet's disease. *Nature genetics*. 2013; 45:319–324. [PubMed: 23396137]
18. Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S, et al. Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. *American journal of human genetics*. 2015; 96:5–20. [PubMed: 25529635]
19. Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, et al. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nature communications*. 2014; 4:4999.
20. Breast Cancer Association Consortium (BCAC) [Internet]. Cambridge (UK): Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK; Available from: <http://www.srl.cam.ac.uk/consortia/bcac/>.
21. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. *Nature genetics*. 2009; 41:1116–1121. [PubMed: 19767753]
22. HapMap project [Internet]. Bethesda (MD): National Institutes of Health, National Library of Medicine, National Center for Biotechnology Information; Available from: <http://hapmap.ncbi.nlm.nih.gov/>
23. 1000 Genomes [Internet]. Bethesda (MD): National Institutes of Health, National Library of Medicine, National Center for Biotechnology Information; c2008–2012 Available from: <http://browser.1000genomes.org/>
24. IMPUTE v.2.2 [Internet]. Oxford (UK): Oxford University; Available from: https://mathgen.stats.ox.ac.uk/impute/impute_v2.html
25. R version 2.13.0 [Internet]. Vienna (Austria): The R Foundation; Available from: <http://www.r-project.org/>
26. Encyclopedia of DNA Elements at UCSC (ENCODE) [Internet]. Santa Cruz (CA): Genome Bioinformatics Group, Center for Biomolecular Science and Engineering at the University of California Santa Cruz; Available from: <http://genome.ucsc.edu/ENCODE/>
27. Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. *Nature methods*. 2012; 9:215–216. [PubMed: 22373907]
28. UCSC Genome Browser [Internet]. Santa Cruz (CA): Genome Bioinformatics Group, Center for Biomolecular Science and Engineering at the University of California Santa Cruz; Available from: <http://genome.ucsc.edu>
29. RegulomeDB [Internet]. Stanford (CA): Center for Genomics and Personalized Medicine at Stanford University; Available from: <http://regulome.stanford.edu/>
30. HaploReg v2 [Internet]. Cambridge (MA): the Broad Institute of MIT and Harvard; Available from: <http://www.broadinstitute.org/mammals/haploreg/haploreg.php>

31. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic acids research*. 2012; 40:D930–D934. [PubMed: 22064851]
32. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, et al. Super-enhancers in the control of cell identity and disease. *Cell*. 2013; 155:934–947. [PubMed: 24119843]
33. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, et al. An atlas of active enhancers across human cell types and tissues. *Nature*. 2014; 507:455–461. [PubMed: 24670763]
34. The Cancer Genome Atlas (TCGA) [Internet]. Bethesda (MD): US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, National Human Genome Research Institute; Available at: <http://cancergenome.nih.gov/>
35. CbioPortal [Internet]. New York (NY): Memorial Sloan Kettering Cancer Center, cBioPortal for Cancer Genomics; Available from: <http://www.cbioportal.org/public-portal/>
36. Pickrell JK, Marioni JC, Pai AA, Degner JF, Engelhardt BE, Nkadori E, et al. Understanding mechanisms underlying human gene expression variation with RNA sequencing. *Nature*. 2010; 464:768–772. [PubMed: 20220758]
37. Li Q, Seo JH, Stranger B, McKenna A, Pe'er I, Laframboise T, et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. *Cell*. 2013; 152:633–641. [PubMed: 23374354]
38. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*. 2012; 486:346–352. [PubMed: 22522925]
39. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. *Bioinformatics*. 2012; 28:1353–1358. [PubMed: 22492648]
40. Wei M, Liu B, Gu Q, Su L, Yu Y, Zhu Z. Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1). *Cellular oncology*. 2013; 36:79–93.
41. Wang XB, Peng WQ, Yi ZJ, Zhu SL, Gan QH. Expression and prognostic value of transcriptional factor sp1 in breast cancer. *Ai zheng = Aizheng = Chinese journal of cancer*. 2007; 26:996–1000. [PubMed: 17927860]
42. Mitchell A, Dass CR, Sun LQ, Khachigian LM. Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNazymes targeting the zinc finger transcription factor EGR-1. *Nucleic acids research*. 2004; 32:3065–3069. [PubMed: 15181171]
43. Eeckhoutte J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. *Genes & development*. 2006; 20:2513–2526. [PubMed: 16980581]
44. Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108:14566–14571. [PubMed: 21873190]
45. Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM, et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. *Cell stem cell*. 2013; 13:87–101. [PubMed: 23827711]
46. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. *Nature*. 2010; 466:1129–1133. [PubMed: 20639862]
47. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. *Nature*. 2010; 468:839–843. [PubMed: 21057493]
48. Koh KP, Yabuuchi A, Rao S, Huang Y, Cunliffe K, Nardone J, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. *Cell stem cell*. 2011; 8:200–213. [PubMed: 21295276]
49. Schoofs T, Berdel WE, Muller-Tidow C. Origins of aberrant DNA methylation in acute myeloid leukemia. *Leukemia*. 2014; 28:1–14. [PubMed: 23958917]

50. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics*. 2010; 26:2336–2337. [PubMed: 20634204]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1. Regional plot of genetic variants associated with breast cancer risk at 4q24

A) The index SNP rs9790517 is plotted in diamond purple. The LD (r^2) for the index SNP with each SNP was computed based on European ancestry subjects included in the 1000 Genome Mar 2012 EUR. P values were from the single-marker analysis based on logistic regression models after adjusted for age, study sites and the first six principal components plus one additional principal component for the LMBC in analyses of data from European descendants. The plot was generated using LocusZoom (50).




Figure 2. Functional annotation of SNPs association with breast cancer risk at 4q24

A) Epigenetic landscape at 4q24 risk locus for breast cancer. From top to bottom, RefSeq genes (*TET2* and *PPA2*), layered H3K4Me1, H3K4Me3 and H3K27Ac histone modifications, DNase clusters, annotation using chromatin states on the ENCODE cell lines, and H3K27Ac histone modification in MCF-7, predicted enhancers reported in the Hnisz et al. study, regulatory elements of enhancers associated with TSS and TSSs from the FANTOM5 project and ChIA-PET interactions in MCF-7 cell (mediated by RNA polymerase 2) between enhancers and *TET2* promoter are shown. The signals of different

layered histone modifications from the same ENCODE cell line are shown in the same color (The detailed color scheme for each ENCODE cell line described in the UCSC genome browser). The red and orange colors in chromatin states refer to active promoter and strong enhancer regions, respectively (The detailed color scheme of the chromatin states described in the previous study (27)). For ChIA-PET track, black lines represented interactions with the promoter region (−1500/+500) of *TET2*, and gray lines represent chromatin interactions that do not involve the *TET2* promoter region. Purple and green lines represent interactions within ± 500 pb of rs73838678 and rs62331150 variants, respectively. B) Epigenetic signals of two potential functional variants rs73838678 and rs62331150. From top to bottom, lanes showing that the variant mapped to TF predicted binding motifs, TF ChIP-Seq binding peaks and DNase I hypersensitivity sites. The corresponding location of the variant is indicated by dashed line. C) LD plot for breast cancer risk associated SNPs at 4q24. In the top lane, two SNPs representing independent association signals are indicated by the black arrows. The index SNP is indicated by the red arrow. In the bottom lane, two LD SNP blocks were shown based on r^2 values, which were computed based on the genotype data from the BCAC.




Figure 3. The association between SNP rs62331150 and *TET2* expression in breast cancer tissues from TCGA

The reference allele G of rs62331150 is significantly associated with the increased gene expression relative to the risk allele T.

Identification of two independent association signals for overall breast cancer risk among women of European ancestry.

Table 1

Signal	SNPs	Position (hg 19)	Alleles ^b	RAF	LD ^c (r ²)	Single Marker Analysis			Conditional Analysis		
						OR (95% CI) ^d	P trend ^d		OR (95% CI) ^e	P trend ^e	
All cases (48,155 cases and 43,612 controls)											
1 ^f	rs9790517 ^a	106084778	T/C	0.23	-	1.05(1.03–1.08)	5.44 × 10 ⁻⁶		1.04(1.02–1.07)	2.51 × 10 ⁻⁴	
2 ^g	rs77928427	106356761	A/C	0.24	0.04	1.05(1.03–1.08)	4.07 × 10 ⁻⁶		1.04(1.02–1.07)	1.86 × 10 ⁻⁴	
ER (+) (28,038 cases and 43,612 controls)											
1	rs9790517 ^a	106084778	T/C	0.23	-	1.06(1.03–1.09)	1.20 × 10 ⁻⁵		1.05(1.02–1.08)	2.49 × 10 ⁻⁴	
2	rs77928427	106356761	A/C	0.24	0.04	1.05(1.02–1.08)	1.40×10 ⁻⁴		1.04(1.01–1.07)	3.07 × 10 ⁻³	
ER (-) (7,786 cases and 43,612 controls)											
1	rs9790517 ^a	106084778	T/C	0.22	-	1.04(0.99–1.08)	0.16		1.02(0.98–1.07)	0.3396	
2	rs77928427	106356761	A/C	0.24	0.04	1.05(1.01–1.09)	0.03		1.04(1.00–1.09)	0.0508	

Abbreviations: OR, odds ratio; CI, confidence interval; RAF, risk allele frequency

^aIndex SNP.

^bRisk/reference allele; risk alleles are shown in bold.

^cr² for linkage disequilibrium with the index SNP rs9790517.

^dAdjusted for age, study and the first six and an additional PC for LMBC study.

^eIncluded both top SNPs and adjusted for other top SNPs, age, study sites and the first six and an additional PC for LMBC study.

^fA total of 23 SNPs cannot be excluded using LR < 1/100 as candidate causal variants (see Supplementary table 1).

^gA total of 4 SNPs cannot be excluded using LR < 1/100 as candidate causal variants (see Supplementary table 1)

Table 2

Haplotype analyses of the lead SNPs in two independent signals in relation to breast cancer risk among women of European ancestry.

Signal					
	rs9790517 ^a	rs77928427	% ^b	OR(95% CI) ^c	P trend ^c
Reference	C	C	62.1	Reference (1.00)	
1	C	A	15.1	1.03(1.00–1.06)	0.06
2	T	C	13.4	1.03(1.00–1.06)	0.09
3	T	A	9.4	1.11(1.07–1.15)	2.31 × 10 ⁻⁸

Abbreviations: OR, odds ratio; CI, confidence interval.

^a Index SNP.

^b Haplotype frequency.

^c Adjusted for age, study and the first six PCs and an additional PC for LMBC study.

Table 3

Association of lead SNPs identified in women of European and non-European descent with breast cancer risk among women of Asian (6,269 cases and 6,624 controls) and African ancestry (1,116 cases and 932 controls).

Top SNPs	Alleles ^b	Single Marker Analysis (Asian)				Single Marker Analysis (African)				
		RAF	LD (r ²) ^c	OR (95% CI) ^d	P trend ^d	RAF	LD (r ²) ^c	OR (95% CI) ^d	P trend ^d	
Identified in women of European descent										
Signal 1	rs9790517 ^a	T/C	0.60	-	1.00(0.95–1.06)	0.93	-	1.21(0.88–1.55)	0.28	
Signal 2	rs77928427	A/C	0.06	0.01	1.02(0.91–1.12)	0.50	0	1.03(0.85–1.22)	0.86	
Identified in women of non-European descent										
	rs1116764	G/A	0.66	0.13	1.10(1.04–1.16)	4.21×10 ⁻⁴	0	1.02(0.81–1.23)	0.98	
	rs79219151	C/T	NA				0.95	0	1.63(1.13–2.13)	7.44×10 ⁻³
	rs112095278	C/T	NA				0.95	0	1.65(1.16–2.14)	4.13×10 ⁻³
	rs144956461	A/T	NA				0.93	0	1.56(1.12–2.01)	6.73×10 ⁻³

Abbreviations: OR, odds ratio; CI, confidence interval; RAF, risk allele frequency.

^a Index SNP

^b Risk/reference allele; risk alleles are shown in bold.

^c r² for linkage disequilibrium with the index SNP rs9790517 in Asians and Africans, respectively.

^d Adjusted for age, study and the first six PC and an additional PC for LMBC study.